Application No. 09/753,136

In the Claims:

Please amend Claims 1, 11, 14, 25, 27 and 28 as follows (the changes in these Claims are shown with strikethrough for deleted matter and <u>underlines</u> for added matter). Claims 2-10, 12, 15-24, 26, and 30-35 have been cancelled. A complete listing of the claims with proper claim identifiers is set forth below.

1. (Currently Amended) A non-irritating anti-viral lotioned tissue product having applied to at least one surface thereof an anti-viral lotion composition comprising:

a virucidal effective amount-about 1% to about 25% of at least one antiviral organic acid, said anti-viral organic acid comprising carboxylic acid having the structure R-COOH, wherein R is C₁-C₆ alkyl carboxyhydroxy;

a topical delivery system about 5% to about 25% of an emollient including at least one polyester, said polyester comprising trimethylpentanediol/adipic isononanoic acid copolymer; and

a cationic surfactant.

- 2. (Cancelled).
- 3. (Cancelled).
- 4. (Cancelled).
- 5. (Cancelled).
- 6. (Cancelled).
- 7. (Cancelled).
- 8. (Cancelled).
- 9. (Cancelled).
- (Cancelled).

Attn: Examiner Neil Levy Appln. Serial No. 09/753,136

11. (Currently Amended) A lotioned tissue product having applied to at least one surface thereof an anti-viral lotion composition comprising:

BRINKS FAX

about 1% to about 25% of at least one anti-viral organic acid, said antiviral organic acid comprising carboxylic acid having the structure R-COOH, wherein R is C₁-C₆ alkyl carboxyhydroxy;

about 5% to about 25% of an emollient including at least one polyester, said polyester comprising trimethylpentanediol/adipic acid copolymer; and a cationic surfactant.

- 12. (Cancelled).
- 13. (Original) The lotioned tissue product of claim 11, wherein said cationic surfactant comprises a quaternary ammonium compound.
- 14. (Currently Amended) A non-irritating, anti-viral lotion composition comprising:

a virucidal effective amount about 1% to about 25% of at least one antiviral organic acid, said anti-viral organic acid comprising carboxylic acid having the structure R-COOH, wherein R is C1-C6 alkyl carboxyhydroxy;

a topical delivery system about 5% to about 25% of an emollient including at least one polyester, said polyester comprising trimethylpentanediol/adipic isononanoic acid copolymer, and

a cationic surfactant.

- 15. (Cancelled).
- 16. (Cancelled).
- 17. (Cancelled).
- 18. (Cancelled).
- 19. (Cancelled).

Application Serial No. 09/753,136 Client/Matter No. KC 14645 (659-764)

- 20. (Cancelled).
- 21 (Cancelled).
- 22. (Cancelled).
- 23. (Cancelled).
- 24. (Cancelled).
- 25. (Currently Amended) A anti-viral lotion composition comprising:
 about 1% to about 25% of at least one anti-viral organic acid, said antiviral organic acid comprising carboxylic acid having the structure R-COOH, wherein R is
 C1-C6 alkyl carboxyhydroxy;

BRINKS FAX

about 5% to about 25% of an emollient including at least one polyester, said polyester comprising trimethylpentanediol/adipic acid copolymer; and a cationic surfactant.

- 26. (Cancelled).
- 27. (Currently Amended) The lotion composition of claim 2625, wherein said cationic surfactant comprises a quaternary ammonium compound.
- 28. (Currently Amended) A method of inhibiting the transfer of a viral infection comprising:

providing anti-viral lotion tissue product having applied to at least one surface thereof an anti-viral lotion composition comprising a virucidal effective amount of about 1% to about 25% of at least one anti-viral organic acid, said anti-viral organic acid comprising carboxylic acid having the structure R-COOH, wherein R is C₁-C₈ alkyl carboxyhydroxy, and a tepisal delivery system about 5% to about 25% of an emollient including at least one polyester, said polyester comprising trimethylpentanediol/adipic acid copolymer, and a cationic surfactant;

contacting a fluid containing at least one virus with said anti-viral tissue product; and

Application Serial No. 09/753,136 Client/Matter No. KC 14645 (659-764)

absorbing said fluid within said absorbent article to contact the fluid with said anti-viral lotion composition.

- 29. (Original) The method of claim 28, further comprising: transferring a portion of the lotion composition to the user of the tissue product.
 - 30. (Cancelled).
 - 31. (Cancelled).
 - 32. (Cancelled).
 - 33. (Cancelled).
 - 34. (Cancelled).
 - 35. (Cancelled),